Investor Presentaiton
9M reported growth was up 11%, with -4%-points contribution from
the Atos Medical acquisition and ~1%-point headwind from currencies
9M 2022/23 Revenue development (DKKm)
1,754m DKK
18,274
-127
633
16,520
1,248
Reported
Organic growth
revenue
9M 21/22
(constant
currencies)
Acquired
growth
Currency effect
Reported
revenue
9M 22/23
Growth
7.6%
3.8%
-0.8%
10.6%
•
9M 2022/23 highlights
Organic growth was 8% or DKK 1,248 million, driven by:
Solid growth in Chronic Care across regions, ex. China
China had a neutral impact on growth in Ostomy Care, with
COVID-19 impact in H1 and double-digit sales growth in Q3
Continence Care growth was driven by solid performance in
Intermittent Catheters, while Collecting Devices contributed
modestly to growth, due to backorders in H1
Solid performance in Voice & Respiratory Care, with
contributions from both Laryngectomy and Tracheostomy
Wound Care growth was broad-based across regions but held
back by backorders. Solid contribution from China since the
lifting of COVID-19 restrictions in the country in Q2
Strong momentum in Interventional Urology with broad-
based growth, led by the US Men's Health business
Acquired revenue contributed 4%-points to reported growth or DKK
633 million, reflecting 4 months impact from Atos Medical
Foreign exchange rates had a negative impact of DKK 127 million or
-0.8%-point on reported growth, mainly related to the depreciation
of GBP and several emerging markets currencies against DKK
62
52
ColoplastView entire presentation